RJA
AGL icon

Raymond James & Associates’s Agilon Health AGL Stock Holding History

Raymond James & Associates’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$49.4K Sell
503
-4
-0.8% -$517 ﹤0.01% 3856
2024
Q2 		$83K Sell
507
-22
-4% -$3.13K ﹤0.01% 3748
2024
Q1 		$80.6K Sell
529
-58
-10% -$9.65K ﹤0.01% 3759
2023
Q4 		$184K Buy
+587
New +$212K ﹤0.01% 3539

Other funds holding AGL

CDR
Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's AGL Position: Q3 2024 in Review

Raymond James & Associates reduced its Agilon Health (AGL) stake by 0.79% in Q3 2024, selling an estimated $517 and leaving 503 shares worth $49.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3856.

Raymond James & Associates first reported a position in AGL in Q4 2023 and has held it in 4 quarters since. The position peaked at $184K in Q4 2023. 209 funds tracked by Wall St. Rank hold AGL as of Q3 2024.

  • Raymond James & Associates held 503 shares of Agilon Health worth $49.4K as of Q3 2024.
  • Raymond James & Associates sold 4 Agilon Health shares in Q3 2024, an estimated $517.
  • Agilon Health made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3856 holding.
  • Raymond James & Associates first reported a position in Agilon Health in Q4 2023 and has held it in 4 quarters since.
  • Raymond James & Associates's Agilon Health position peaked at $184K in Q4 2023.
  • 209 funds tracked by Wall St. Rank held Agilon Health as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.